Chemical formula: C₁₅H₁₀Cl₂N₄O₆ Molecular mass: 413.17 g/mol
Opicapone is a peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor endowed with a high binding affinity (sub-picomolar). Opicapone is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease, leading to an increase of levodopa plasma levels thereby improving the clinical response to levodopa.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N04BX04 | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ONGENTYS Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Opicapone is an active ingredient of these brands:
United States (US)Finland (FI)Japan (JP)Netherlands (NL)Romania (RO)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
